Equities

Celon Pharma SA

Celon Pharma SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (PLN)27.70
  • Today's Change0.150 / 0.54%
  • Shares traded39.01k
  • 1 Year change+79.40%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 19-Sep-24
Select bar for recommendation details.
Recommendations19-Sep-24
Buy0
Outperform1
Hold3
Sell1
Strong Sell0

Share price forecast in PLN

The 5 analysts offering 12 month price targets for Celon Pharma SA have a median target of 16.00, with a high estimate of 39.00 and a low estimate of 12.00. The median estimate represents a -42.24% decrease from the last price of 27.70.
High40.8%39.00
Med-42.2%16.00
Low-56.7%12.00

Dividends

In 2023, Celon Pharma SA reported a dividend of 0.08 PLN, which represents a 11.11% decrease from last year. The 2 analysts covering the company expect dividends of 0.10 PLN for the upcoming fiscal year, an increase of 18.75%.
Div growth (TTM)-11.11%
More ▼

Earnings history & estimates in PLN

On Nov 23, 2022, losses of -0.01 per share.
Average growth rate0.00%
Celon Pharma SA reported annual 2023 losses of -0.55 per share on Apr 24, 2024.
Average growth rate-33.88%
More ▼

Revenue history & estimates in PLN

Celon Pharma SA had 2nd quarter 2024 revenues of 65.61m. This bettered the 63.85m consensus of the 2 analysts covering the company. This was 49.49% above the prior year's 2nd quarter results.
Average growth rate+4.84%
Celon Pharma SA had revenues for the full year 2023 of 216.57m. This was 11.29% above the prior year's results.
Average growth rate+22.05%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.